What we do

Subscribe to
our newsletter!

Subscribe here

Educational clips

Doctor Thierry Facon, professor of Haematology at Lille University Hospital in France explains the results of the Phase 3 IMROZ study, comparing isatuximab, bortezomib, lenalidomide and dexamethasone, known as Isa-VRd, ...versus VRd for transplant-ineligible patients with newly diagnosed myeloma at the European Hematology Association annual congress in Madrid, Spain.[+] Show More
EHA2024 |The IMROZ study
Doctor Thierry Facon, professor of Haematology at Lille University ...
EHA 2024 | The DREAMM-8 study
Doctor Dimopoulos explains the DREAMM-8 study, one of the ...
EHA 2024 | DREAMM 7 study
Doctor Dimopoulos explains the DREAMM-7 study presented at the 2024 ...
EHA 2024 | Fair pricing: Does the value of new medicines in hematology justify the high prices?
Professor Doctor Uyl-de Groot explains fair pricing in haematology ...
EHA 2024 | Whose needs exactly? Unmet medical need in the EU pharmaceutical legislation
Maria Cavaller Bellaubi, Patient Engagement and Development Director, ...
EHA 2024 | CAMMA 2 study
Doctor Kumar explains the CAMMA 2 study presented at the 2024 European ...
ASH 2023 | ATLAS trial: MRD assessment in peripheral blood
In this video, Dr. Krzysztof Giannopoulos, Department of Experimental ...
ASH 2023 | Minimal Residual Disease (MRD) measurement in myeloma
In this video, Carmen Gonzalez, Cancer Center Clinica Universidad de ...
ASH 2023 | PERSEUS study: DARA + VRd in myeloma
In this video, Prof. Pieter Sonneveld, Head of the Department of ...
ASH 2023 | The iStopMM study: myeloma screening
In this video, Dr.Sæmundur Rögnvaldsson, Faculty of Medicine, ...
ASH 2023 | HBI0101 therapy: CAR-T in AL amyloidosis
In this video, Dr. Moshe Gatt, Department of Haematology, Hebrew ...
ESMO 2023 | How digitalisation helps personalised care throughout the patient journey
In this video, the chair of the ESMO Patient Advocates Working Group ...
1 of 8
[wpcode id="97810"]